{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:41:01Z","timestamp":1791639661218,"version":"4.3.4"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec id=\"ab-doi230038-4\"><jats:title>Importance<\/jats:title><jats:p>The gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals and patients with melanoma or if microbiota profiles differ among patients with different stages of melanoma. Defining gut microbiota profiles in individuals without melanoma and those with early-stage and late-stage melanoma may reveal features associated with disease progression.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230038-5\"><jats:title>Objective<\/jats:title><jats:p>To characterize and compare gut microbiota profiles between healthy volunteers and patients with melanoma and between patients with early-stage and late-stage melanoma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230038-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This single-site case-control study took place at an academic comprehensive cancer center. Fecal samples were collected from systemic treatment\u2212naive patients with stage I to IV melanoma from June 1, 2015, to January 31, 2019, and from healthy volunteers from June 1, 2021, to January 31, 2022. Patients were followed up for disease recurrence until November 30, 2021.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230038-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Fecal microbiota was profiled by 16S ribosomal RNA sequencing. Clinical and pathologic characteristics, treatment, and disease recurrence were extracted from electronic medical records. Fecal microbiome diversity, taxonomic profiles and inferred functional profiles were compared between groups.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230038-8\"><jats:title>Results<\/jats:title><jats:p>A total of 228 participants were enrolled (126 men [55.3%]; median age, 59 [range, 21-90] years), including 49 volunteers without melanoma, 38 patients with early-stage melanoma (29 with stage I or melanoma in situ and 9 with stage II), and 141 with late-stage melanoma (66 with stage III and 75 with stage IV). Community differences were observed between patients with melanoma and volunteers. Patients with melanoma had a higher relative abundance of <jats:italic>Fusobacterium<\/jats:italic> compared with controls on univariate analysis (0.19% vs 0.003%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), but this association was attenuated when adjusted for covariates (log2 fold change of 5.18 vs controls; <jats:italic>P<\/jats:italic>\u2009=\u2009.09). Microbiomes were distinct between patients with early-stage and late-stage melanoma. Early-stage melanoma had a higher alpha diversity (Inverse Simpson Index 14.6 [IQR, 9.8-23.0] vs 10.8 [IQR, 7.2-16.8]; <jats:italic>P<\/jats:italic>\u2009=\u2009.003), and a higher abundance of the genus <jats:italic>Roseburia<\/jats:italic> on univariate analysis (2.4% vs 1.2%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) though statistical significance was lost with covariate adjustment (log2 fold change of 0.86 vs controls; <jats:italic>P<\/jats:italic>\u2009=\u2009.13). Multiple functional pathways were differentially enriched between groups. No associations were observed between the microbial taxa and disease recurrence in patients with stage III melanoma treated with adjuvant immunotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230038-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this case-control study suggest that fecal microbiota profiles were significantly different among patients with melanoma and controls and between patients with early-stage and late-stage melanoma. Prospective investigations of the gut microbiome and changes that occur with disease progression may identify future microbial targets for intervention.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2955","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T15:34:59Z","timestamp":1693409699000},"page":"1076","source":"Crossref","is-referenced-by-count":24,"title":["Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma"],"prefix":"10.1001","volume":"159","author":[{"given":"Russell G.","family":"Witt","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Cass","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffaney","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Damania","sequence":"additional","affiliation":[{"name":"Platform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie E.","family":"Nelson","sequence":"additional","affiliation":[{"name":"John P. and Kathrine G. McGovern Medical School at UTHealth Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sirmans","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chelvanambi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Mishra","sequence":"additional","affiliation":[{"name":"John P. and Kathrine G. McGovern Medical School at UTHealth Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Wong","sequence":"additional","affiliation":[{"name":"John P. and Kathrine G. McGovern Medical School at UTHealth Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim J.","family":"Ajami","sequence":"additional","affiliation":[{"name":"John P. and Kathrine G. McGovern Medical School at UTHealth Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie R.","family":"Daniel","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi230038r1","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S1470-2045(18)30952-5","article-title":"Modulating the microbiome to improve therapeutic response in cancer.","volume":"20","author":"McQuade","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6575","key":"doi230038r2","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"issue":"6371","key":"doi230038r3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients.","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"10","key":"doi230038r4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","article-title":"Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients.","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia"},{"issue":"6371","key":"doi230038r5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients.","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"6","key":"doi230038r6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"doi230038r7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13073-019-0672-4","article-title":"Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.","volume":"11","author":"Peters","year":"2019","journal-title":"Genome Med"},{"issue":"4","key":"doi230038r8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes.","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"issue":"6","key":"doi230038r9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","article-title":"The gut microbiota influences anticancer immunosurveillance and general health.","volume":"15","author":"Routy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"doi230038r10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy.","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"doi230038r11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"doi230038r12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.","volume":"28","author":"Lee","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"doi230038r13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"issue":"6382","key":"doi230038r14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6529","key":"doi230038r15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"6529","key":"doi230038r16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients.","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"4","key":"doi230038r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors.","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"doi230038r18","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.","volume":"12","author":"Luu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"doi230038r19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41467-019-09525-y","article-title":"Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-\/- mice.","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"doi230038r22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12866-022-02458-5","article-title":"Dysbiosis of skin microbiome and gut microbiome in melanoma progression.","volume":"22","author":"Mekadim","year":"2022","journal-title":"BMC Microbiol"},{"issue":"3","key":"doi230038r23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrmicro.2017.157","article-title":"The human skin microbiome.","volume":"16","author":"Byrd","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"doi230038r24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bjd.20811","article-title":"Do the gut and skin microbiomes share thoughts on melanoma development?","volume":"186","author":"Camara","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230038r25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bjd.20626","article-title":"Early melanoma invasivity correlates with gut fungal and bacterial profiles.","volume":"186","author":"Vitali","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi230038r26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.v67.6","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"doi230038r29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/ismej.2012.8","article-title":"Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms.","volume":"6","author":"Caporaso","year":"2012","journal-title":"ISME J"},{"issue":"3","key":"doi230038r30","doi-asserted-by":"publisher","first-page":"e00218","DOI":"10.1128\/mSystems.00218-17","article-title":"KatharoSeq enables high-throughput microbiome analysis from low-biomass samples.","volume":"3","author":"Minich","year":"2018","journal-title":"mSystems"},{"issue":"23","key":"doi230038r31","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1128\/AEM.01541-09","article-title":"Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.","volume":"75","author":"Schloss","year":"2009","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"doi230038r33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2307\/1942268","article-title":"An ordination of the upland forest communities of southern Wisconsin.","volume":"27","author":"Bray","year":"1957","journal-title":"Ecol Monogr"},{"issue":"1","key":"doi230038r34","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41467-020-17041-7","article-title":"Analysis of compositions of microbiomes with bias correction.","volume":"11","author":"Lin","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"doi230038r35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies.","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"4148","key":"doi230038r38","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/163688a0","article-title":"Measurement of diversity.","volume":"163","author":"Simpson","year":"1949","journal-title":"Nature"},{"issue":"12","key":"doi230038r39","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","article-title":"Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.","volume":"65","author":"Mima","year":"2016","journal-title":"Gut"},{"issue":"3","key":"doi230038r40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"issue":"5","key":"doi230038r41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaoncol.2015.1377","article-title":"Fusobacterium nucleatum and T cells in colorectal carcinoma.","volume":"1","author":"Mima","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"doi230038r42","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s13277-015-4724-0","article-title":"Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut.","volume":"37","author":"Bashir","year":"2016","journal-title":"Tumour Biol"},{"issue":"3","key":"doi230038r43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti\u2013PD-1.","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"doi230038r44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/2159-8290.CD-21-0999","article-title":"Cancer induces a stress ileopathy depending on \u00df-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis.","volume":"12","author":"Yonekura","year":"2022","journal-title":"Cancer Discov"},{"issue":"7402","key":"doi230038r45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome.","volume":"486","author":"Huttenhower","year":"2012","journal-title":"Nature"},{"issue":"7285","key":"doi230038r46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing.","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"issue":"1","key":"doi230038r47","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.1038\/s41598-021-86816-9","article-title":"Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.","volume":"11","author":"Neuzillet","year":"2021","journal-title":"Sci Rep"},{"key":"doi230038r48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fmicb.2018.00862","article-title":"Oral microbiota community dynamics associated with oral squamous cell carcinoma staging.","volume":"9","author":"Yang","year":"2018","journal-title":"Front Microbiol"},{"issue":"17","key":"doi230038r49","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.3390\/ijms21176207","article-title":"Involvement of Fusobacterium species in oral cancer progression: a literature review including other types of cancer.","volume":"21","author":"Fujiwara","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"doi230038r50","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"doi230038r51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1101\/gr.126573.111","article-title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.","volume":"22","author":"Kostic","year":"2012","journal-title":"Genome Res"},{"issue":"2","key":"doi230038r52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1101\/gr.126516.111","article-title":"Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.","volume":"22","author":"Castellarin","year":"2012","journal-title":"Genome Res"},{"issue":"11","key":"doi230038r53","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.3748\/wjg.v22.i11.3227","article-title":"Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients.","volume":"22","author":"Li","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"doi230038r54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u00df-catenin signaling via its FadA adhesin.","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"2","key":"doi230038r55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.chom.2016.07.006","article-title":"Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc.","volume":"20","author":"Abed","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"3","key":"doi230038r56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41579-018-0129-6","article-title":"Fusobacterium nucleatum:  symbiont, opportunist and oncobacterium.","volume":"17","author":"Brennan","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"doi230038r57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/19490976.2017.1361093","article-title":"Assessing gut microbiota perturbations during the early phase of infectious diarrhea in Vietnamese children.","volume":"9","author":"The","year":"2018","journal-title":"Gut Microbes"},{"issue":"6","key":"doi230038r58","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/gb-2014-15-6-r76","article-title":"Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition.","volume":"15","author":"Pop","year":"2014","journal-title":"Genome Biol"},{"key":"doi230038r59","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/694629","article-title":"Microbial translocation in chronic liver diseases.","volume":"2012","author":"Pinzone","year":"2012","journal-title":"Int J Microbiol"},{"issue":"6264","key":"doi230038r60","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"1","key":"doi230038r61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chom.2017.11.004","article-title":"Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration.","volume":"23","author":"Schroeder","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"6","key":"doi230038r62","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1079\/BJN20041150","article-title":"Contribution of acetate to butyrate formation by human faecal bacteria.","volume":"91","author":"Duncan","year":"2004","journal-title":"Br J Nutr"},{"issue":"7","key":"doi230038r63","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1128\/AEM.69.7.4320-4324.2003","article-title":"Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces.","volume":"69","author":"Hold","year":"2003","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"doi230038r64","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","article-title":"Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity.","volume":"33","author":"He","year":"2021","journal-title":"Cell Metab"},{"issue":"10","key":"doi230038r65","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","article-title":"Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors.","volume":"29","author":"Montalban-Arques","year":"2021","journal-title":"Cell Host Microbe"},{"key":"doi230038r27","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3_47","volume-title":"Melanoma of the Skin","author":"Gershenwald","year":"2017"},{"key":"doi230038r20","unstructured":"Effect of diet on the immune system in patients with stage III-IV melanoma receiving immunotherapy, DIET study (DIET). ClinicalTrials.gov identifier: NCT04645680. Updated April 6, 2023. Accessed July 31, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04645680"},{"key":"doi230038r21","unstructured":"The effect of diet and exercise on immunotherapy and the microbiome (EDEN). ClinicalTrials.gov identifier: NCT04866810. Updated July 13, 2023. Accessed July 31, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04866810"},{"key":"doi230038r28","unstructured":"Association between gut microbiome and dietary determinants and vaccine response. ClinicalTrials.gov identifier: NCT05239403. Updated February 14, 2023. Accessed March 7, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05239403"},{"key":"doi230038r32","unstructured":"Differential gene expression analysis based on the negative binomial distribution. February 22, 2021. Accessed January 5, 2023. https:\/\/rdrr.io\/bioc\/DESeq2\/"},{"key":"doi230038r36","unstructured":"phyloseq: handling and analysis of high-throughput microbiome census data. November 8, 2020. Accessed December 18, 2022. https:\/\/rdrr.io\/bioc\/phyloseq\/"},{"key":"doi230038r37","unstructured":"R Project for Statistical Computing. Index of\/src\/base\/R-4. October 31, 2022. Accessed January 5, 2023. https:\/\/cran.r-project.org\/src\/base\/R-4\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2808971\/jamadermatology_witt_2023_oi_230038_1698251756.20705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:00:31Z","timestamp":1698253231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2808971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2955","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}